Efficacy and safety of low-intensity extracorporeal shock wave therapy in the treatment of ED: A meta-analysis of randomized controlled trials.
- Author:
Dun-Sheng MO
1
;
Xu-Xin ZHAN
2
;
Hong-Wei SHI
3
;
Hong-Cai CAI
4
;
Jun MENG
5
;
Jing ZHAO
2
;
Xue-Jun SHANG
6
Author Information
1. Department of Urology， Liuzhou Workers' Hospital / The Fourth Affiliated Hospital of Guangxi Medical University， Liuzhou， Guangxi 545005， China.
2. Department of Reproductive Medicine, Xi'an No. 4 Hospital, Xi'an, Shaanxi 710004, China.
3. Department of Traditional Chinese Medicine, Xi'an No. 4 Hospital, Xi'an, Shaanxi 710004, China.
4. Family Planning Research Institute / Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
5. Deshengchang Clinic of Traditional Chinese Medicine, Xianyang, Shaanxi 712000, China.
6. Department of Andrology, Jinling Hospital Affiliated to Nanjing University School of Medicine, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- Keywords:
International Index of Erectile Function index;
erectile dysfunction;
erection hardness score;
meta-analysis;
low-intensity extracorporeal shock wave therapy
- From:National Journal of Andrology
2019;25(3):257-264
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of low-intensity extracorporeal shock wave therapy (LI-ESWT) in the treatment of ED based on the available clinical evidence.
METHODS:We searched PubMed, MEDLINE, EMBASE, Cochrane Library, CNKI, VIP, CBM and Wanfang Database up to June 2018 for published randomized controlled trials on the treatment of ED by LI-ESWT. We performed literature screening, data extraction and quality evaluation according to inclusion and exclusion criteria, and conducted a meta-analysis of the data obtained using the RevMan 5.3 software.
RESULTS:A total of 595 ED cases in 8 double-blind randomized controlled trials (RCT) were included in this study, 362 in the LI-ESWT and 233 in the control group. Compared with the controls, the patients treated by LI-ESWT showed significantly improved IIEF (WMD = 1.70, 95% CI: 0.44－2.96, P = 0.008) and erection hardness score (EHS) (RR = 11.72, 95% CI: 5.13－26.80, P < 0.01). The IIEF scores of the patients were markedly increased at 4 and 24 weeks after LI-ESWT (WMD = 1.43, 95% CI: 0.10－2.75, P = 0.03; WMD = 3.09, 95% CI: 1.49－4.68, P = 0.0002), as well as after the 10th to 12th treatment (WMD = 1.81, 95% CI: 0.31－3.31, P = 0.02) though not after the 5th to 6th (WMD = 1.88, 95% CI: －2.10 to 5.86, P = 0.35). LI-ESWT also significantly increased the IIEF scores in the patients with the baseline IIEF ≥12 (WMD = 2.13, 95% CI: 0.51－3.75, P = 0.01) but not in those with the baseline IIEF ≤11 (WMD = 1.04, 95% CI: －0.96 to 3.03, P = 0.31). No significant adverse events were reported in the 8 RCTs.
CONCLUSIONS:As a non-invasive treatment, LI-ESWT is safe and effective and can significantly improve IIEF and EHS in ED patients.
